PENG Jumps 16.6%, Leads EPS Revision Screen Winners
Penguin Solutions (PENG) surged 16.6% to $71.57 since being flagged by our EPS revision screener on October 2, as its forward growth estimate hit 29.2%. Sable Offshore (SOC), JBS, Wealthfront (WLTH), and 20/20 Biolabs (AIDX) also gained after upward EPS estimate revisions, with SOC posting a 5.1 percentage-point bump to 152% growth.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| PENG | Technology | 2026-10-02 | N/A | +16.6% |
| SOC | Energy | 2026-10-02 | +5.1pp | +10.0% |
| JBS | Consumer Defensive | 2026-10-02 | +1.4pp | +9.2% |
| WLTH | Technology | 2026-10-02 | N/A | +8.6% |
| AIDX | Healthcare | 2026-10-05 | N/A | +8.6% |
Why did PENG stock jump in October 2026?
PENG jumped 16.6% to $71.57 after its forward EPS growth estimate was revised to 29.2% on October 2.
The move accelerated on October 7 when the company reported record fiscal Q4 sales of $567 million, up 68%, and non-GAAP EPS of $1.00 that beat the 77-cent consensus, while raising FY27 guidance to $4.45 EPS—well above the $3.38 consensus. Analysts responded with price target hikes: Rosenblatt moved to $100 from $80, saying Penguin pulled its bull case forward by a full year, and Stifel raised its target to $85 from $75. Integrated Memory revenue surged 158% year over year on AI infrastructure demand, including a new 36,000-GPU AI factory in Norway backed by $10 billion in contracted capacity, confirming the earnings revision that first caught the screener's attention.
PENG EPS revision history → · Screener snapshot from 2026-10-02 →
FAQ: PENG
Why did PENG stock jump on October 7, 2026?
PENG jumped 16.6% to $71.57 after reporting a record fiscal Q4 with $567 million in sales (+68%) and $1.00 non-GAAP EPS, well above the 77-cent estimate, and raising FY27 EPS guidance to $4.45 versus the $3.38 consensus.
Is PENG a buy after its recent rally?
Analysts are mixed: Rosenblatt and Stifel raised targets to $100 and $85 with Buy ratings, while Barclays kept an Underweight rating and a $60 target, flagging expected gross-margin pressure.
What is PENG's EPS growth estimate for next year?
PENG's forward EPS growth estimate stands at 29.2% per the screener, following the company's raised FY27 guidance of $4.45 non-GAAP EPS, representing about 55% growth from fiscal 2026.
Why did SOC stock jump in October 2026?
SOC gained 10.0% to $3.86 since October 2, when its next-year EPS growth estimate was revised up by 5.1 percentage points to 152.0%.
The upward revision reflects improving sentiment for the energy sector, where offshore oil producers are seeing estimate hikes on firmer crude prices and operational progress. No company-specific news was found in the window, but the screener's early detection captured the estimate revision before the broader market fully repriced the growth outlook, driving the subsequent move.
SOC EPS revision history → · Screener snapshot from 2026-10-02 →
FAQ: SOC
Why did SOC stock rise 10% in early October 2026?
SOC rose 10% to $3.86 after its next-year EPS growth estimate was revised from 146.9% to 152.0% on October 2, reflecting improved sector fundamentals for offshore energy producers.
Is SOC a buy after its recent surge?
The stock's 10% gain followed a 5.1-point upward EPS revision to 152% growth, but without company-specific news in the window, investors should weigh the move against broader energy sector trends and crude price volatility.
What is SOC's EPS growth estimate for next year?
SOC's next-year EPS growth estimate stands at 152.0%, a 5.1 percentage-point increase from the prior 146.9% estimate as of October 2, 2026.
Why did JBS stock jump in October 2026?
JBS climbed 9.2% to $12.75 since October 2, when its next-year EPS growth estimate ticked up 1.4 percentage points to 83.0%.
The meat-processing giant, sector-classified as Consumer Defensive, benefits from stabilizing protein demand and cost controls, though no company-specific earnings news emerged in the window. The screener's early flag on the estimate revision preceded the price gain, suggesting the market gradually absorbed the improved earnings outlook amid broader sector rotation into defensive names.
JBS EPS revision history → · Screener snapshot from 2026-10-02 →
FAQ: JBS
Why did JBS stock gain 9.2% in early October 2026?
JBS rose 9.2% to $12.75 after its next-year EPS growth estimate was revised upward by 1.4 percentage points to 83.0% on October 2, reflecting improving earnings prospects in the protein sector.
Is JBS a buy after its recent rally?
The stock's 9.2% gain followed an EPS growth revision to 83.0%; with no company-specific news in the window, investors should evaluate the move against broader consumer defensive sector trends and protein market fundamentals.
What is JBS's EPS growth estimate for next year?
JBS's next-year EPS growth estimate is 83.0%, up 1.4 percentage points from 81.7% as of October 2, 2026.
Why did WLTH stock jump in October 2026?
WLTH rose 8.6% to $10.89 since October 2, when the screener detected its forward EPS growth estimate at 33.3%.
The wealth-management technology firm, recent to public markets, gained as investors rotated into fintech names with strong growth profiles, though no earnings-specific news surfaced in the window. The estimate itself, standing at 33.3% next-year growth, provided the fundamental catalyst that the screener captured before the market fully reflected the improved outlook in the share price.
WLTH EPS revision history → · Screener snapshot from 2026-10-02 →
FAQ: WLTH
Why did WLTH stock gain 8.6% in early October 2026?
WLTH rose 8.6% to $10.89 after the screener flagged its forward EPS growth estimate at 33.3% on October 2, signaling strong expected earnings growth in the wealth-management technology space.
Is WLTH a buy after its recent surge?
WLTH's 8.6% gain followed the detection of a 33.3% forward EPS growth estimate; with no company-specific news in the window, investors should assess the move against broader fintech sector momentum and the stock's post-IPO trading history.
What is WLTH's EPS growth estimate for next year?
WLTH's current forward EPS growth estimate for next year is 33.3%, as detected by the screener on October 2, 2026.
Why did AIDX stock jump in October 2026?
AIDX jumped 8.6% to $0.38 after the screener identified its forward EPS growth estimate at 26.9% on October 5.
The micro-cap healthcare company, trading below $1, attracted speculative interest as investors sought small-cap biotech names with positive earnings trajectories, though no earnings-related news was reported in the window. The estimate revision captured by the screener signaled improving fundamentals that the market subsequently bid up, even without a specific catalyst.
AIDX EPS revision history → · Screener snapshot from 2026-10-05 →
FAQ: AIDX
Why did AIDX stock jump 8.6% in early October 2026?
AIDX rose 8.6% to $0.38 after the screener detected its forward EPS growth estimate at 26.9% on October 5, signaling expected earnings growth for the micro-cap healthcare firm.
Is AIDX a buy after its recent rally?
AIDX's 8.6% gain followed the detection of a 26.9% forward EPS growth estimate; however, as a sub-$1 micro-cap with no company-specific news in the window, the stock carries elevated risk and volatility.
What is AIDX's EPS growth estimate for next year?
AIDX's next-year EPS growth estimate is 26.9%, as identified by the EPS revision screener on October 5, 2026.
Today's top performers, led by Penguin Solutions' 16.6% surge on a strong earnings beat and raised guidance, show that upward EPS estimate revisions continue to drive outsized gains, particularly in AI infrastructure and technology. The breadth across energy, consumer defensive, and healthcare suggests the revision-driven rally is not confined to a single sector, signaling broad-based earnings optimism.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →